Transplantation as disease modifying therapy in the era of gene therapy medicinal products – health policy considerations
Margreet Wagenmakers, Anna Lehman, Caroline den Hoed, Laura van Dussen, Mirjam Langeveld, Sandra Sirrs · 2026
Read Transplantation as disease modifying therapy in the era of gene therapy medicinal products – health policy considerations by Margreet Wagenmakers, Anna Lehman, Caroline den Hoed, Laura van Dussen, Mirjam Langeveld, Sandra Sirrs (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13471253.txt.
Description
A peer-reviewed research article from Europe PMC (2026). BackgroundNew gene therapy medicinal products [GTMP] are being considered as alternatives to liver transplant [LTx] for some patients with inherited metabolic diseases [IMDs] but pose unique challenges for health policy makers.MethodsPublished data on LTx and GTMP in human patients with urea cycle defects [UCD], glycogen storage disease type 1a [GSD1a], methylmalonic aciduria [MMA] and propionic aciduria [PA] were reviewed for efficacy, safety, data quality and health policy considerations.ResultsLTx can reduce [MMA, PA] or eliminate [UCD, GSD1a] metabolic decompensation and improve quality of
Catalog record
| CREATOR | Margreet Wagenmakers, Anna Lehman, Caroline den Hoed, Laura van Dussen, Mirjam Langeveld, Sandra Sirrs |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |